PRIORITY REVIEW

SOURCE: Investors.AscendisPharma.com (June 2, 2025) – Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared…